Clinical trial
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced…
NCT00081315 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00081315 |
|---|---|
| Title | Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer |
| Official title | Phase II, Randomized, Double-Blind, Multicenter Trial of Subcutaneous Amifostine (Ethyol®) Versus Placebo in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophagitis, Pneumonitis, Non-Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Amifostine |
| Enrollment | 130 |
| Start date | Nov 1, 2003 |
| Completion | Aug 1, 2006 |
| First posted | Apr 9, 2004 |
| Last update posted | Aug 21, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: